Literature DB >> 16645266

Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient.

A Arzuaga1, A Isla, A R Gascón, J Maynar, E Corral, J L Pedraz.   

Abstract

BACKGROUND/AIM: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone.
METHODS: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula.
RESULTS: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH.
CONCLUSION: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645266     DOI: 10.1159/000092921

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.

Authors:  Takehito Yamamoto; Nobuhiro Yasuno; Shoichi Katada; Akihiro Hisaka; Norio Hanafusa; Eisei Noiri; Naoki Yahagi; Toshiro Fujita; Hiroshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 4.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

5.  Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.

Authors:  M G Vossen; D Knafl; M Haidinger; R Lemmerer; M Unger; S Pferschy; W Lamm; A Maier-Salamon; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

Review 7.  Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.

Authors:  Marta Ulldemolins; Sergi Vaquer; Mireia Llauradó-Serra; Caridad Pontes; Gonzalo Calvo; Dolors Soy; Ignacio Martín-Loeches
Journal:  Crit Care       Date:  2014-06-23       Impact factor: 9.097

8.  β-lactam antibiotic concentrations during continuous renal replacement therapy.

Authors:  Marjorie Beumier; Giuseppe Stefano Casu; Maya Hites; Lucie Seyler; Frederic Cotton; Jean-Louis Vincent; Frédérique Jacobs; Fabio Silvio Taccone
Journal:  Crit Care       Date:  2014-05-22       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.